Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Medtronic plc

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

ADVANCED COMPUTE POWER, BUILT ON NVIDIA INFRASTRUCTURE, ENABLES REAL-TIME DECISION SUPPORT DURING THE PROCEDURE FDA-CLEARED INSTRUMENT EXIT POINT (IEP),THE FIRST REAL-TIME AI APPLICATION FOR ROBOTIC PROCEDURES FROM MEDTRONIC, ADVANCES APRECISE, PREDICTABLE,ANDPERSONALIZEDFUTURE FOR SURGERY GALWAY, IRELAND, JULY 21, 2026 /PRNEWSWIRE/ -- MEDTRONIC (NYSE: MDT),A GLOBAL LEADER IN HEALTHCARE TECHNOLOGY, IS PRESENTING AN EARLY LOOK AT ITS NEXT-GENERATION COMPUTE PLATFORMFOR THE OPERATING ROOM. TOUCH SURGERY AIDE  AN AI-NATIVE SURGICAL COMPUTINGPLATFORMTHAT POWERS THE TOUCH SURGERY ECOSYSTEM  ENABLES REAL-TIME ARTIFICIAL INTELLIGENCE DURING PROCEDURES.

A NEW ERA FOR SURGERY WITH REAL-TIME AI: MEDTRONIC TO UNVEIL TOUCH SURGERY AIDE, THE NEXT-GENERATION COMPUTE PLATFORM FOR THE OPERATING ROOM AT SOCIETY OF ROBOTIC SURGERY 2026

GALWAY, IRELAND, JULY 20, 2026 /PRNEWSWIRE/ -- MEDTRONIC PLC (NYSE: MDT), A GLOBAL LEADER IN HEALTHCARE TECHNOLOGY, TODAY ANNOUNCED THAT IT WILL REPORT FINANCIAL RESULTS ON TUESDAY, SEPTEMBER 1, 2026, FOR ITS FIRST QUARTER OF FISCAL YEAR 2027, WHICH ENDS ON FRIDAY, JULY 31, 2026. A NEWS RELEASE CONTAINING SUMMARY FINANCIAL INFORMATION WILL BE ISSUED AT 5:45 A.M.

MEDTRONIC TO ANNOUNCE FINANCIAL RESULTS FOR ITS FIRST QUARTER OF FISCAL YEAR 2027

ACQUISITION ADDS CATEGORY-DEFINING SPRINT PNS TECHNOLOGY TO MEDTRONIC'S PAIN THERAPY PORTFOLIOTHE BROADEST IN THE INDUSTRY. GALWAY, IRELAND, JULY 16, 2026 /PRNEWSWIRE/ -- MEDTRONIC PLC (NYSE: MDT), A GLOBAL LEADER IN HEALTHCARE TECHNOLOGY, TODAY ANNOUNCED IT HAS COMPLETED ITS ACQUISITION OF SPR THERAPEUTICS, INC. (SPR), A PRIVATELY HELD MEDICAL TECHNOLOGY COMPANY AND RECOGNIZED LEADER IN SHORT-TERM, PERCUTANEOUS PERIPHERAL NERVE STIMULATION (PNS) THERAPIES FOR CHRONIC AND ACUTE PAIN MANAGEMENT.

MEDTRONIC COMPLETES ACQUISITION OF SPR, EXPANDING PATIENT ACCESS TO MINIMALLY INVASIVE, NON-OPIOID TREATMENT OF CHRONIC AND ACUTE PAIN

ACQUISITION DELIVERS SIMPLICITY AND ACCESS, SUPPORTING PHYSICIANS ACROSS THE FULL PROCEDURAL WORKFLOW GALWAY, IRELAND, JUNE 12, 2026 /PRNEWSWIRE/ -- MEDTRONIC PLC (NYSE: MDT), A GLOBAL LEADER IN HEALTHCARE TECHNOLOGY, TODAY ANNOUNCED IT HAS COMPLETED ITS ACQUISITION OF SCIENTIA VASCULAR, A PRIVATELY-HELD MEDICAL DEVICE COMPANY IN SALT LAKE CITY. THE ACQUISITION IS VALUED AT $550 MILLION, SUBJECT TO CUSTOMARY ADJUSTMENTS, WITH POTENTIAL UNDISCLOSED EARN-OUT AND MILESTONE PAYMENTS POST-ACQUISITION.

MEDTRONIC COMPLETES ACQUISITION OF SCIENTIA VASCULAR, SEAMLESSLY INTEGRATING ACCESS AND THERAPEUTIC PORTFOLIOS FOR NEUROVASCULAR CARE

COMPANY ALSO ANNOUNCES 510(K) PENDING FOR LIGASURE RAS MARYLAND INSTRUMENT ON THE HUGO RAS SYSTEM, AND 510(K) CLEARANCE FOR PROGRIP ADVANCED SELF-GRIPPING POLYPROPYLENE MESH FOR USE IN ROBOTIC-ASSISTED VENTRAL HERNIA REPAIR SURGERIES GALWAY, IRELAND, JUNE 3, 2026 /PRNEWSWIRE/ -- MEDTRONIC (NYSE: MDT), A GLOBAL LEADER IN HEALTHCARE TECHNOLOGY, TODAY ANNOUNCED SIGNIFICANT MILESTONES TO UNLOCK EXPANDED INDICATIONS FOR THE HUGO ROBOTIC-ASSISTED SURGERY (RAS) SYSTEM IN THE UNITED STATES AND TO SHAPE THE FUTURE OF SURGERY. GENERAL SURGERY INDICATION INCLUDING HERNIA REPAIR  510(K) CLEARANCE SUBMITTED EMBRACE GYNECOLOGY INVESTIGATIONAL DEVICE EXEMPTION (IDE) CLINICAL STUDY  COMPLETED ENROLLMENT GYNECOLOGIC SURGERY INDICATION  510(K) CLEARANCE SUBMITTED LIGASURE RAS MARYLAND INSTRUMENT  510(K) CLEARANCE SUBMITTED PROGRIP ADVANCED MESH FOR USE IN ROBOTIC-ASSISTED VENTRAL HERNIA REPAIR  510(K) CLEARANCE RECEIVED THESE MILESTONES BUILD MOMENTUM FOR MEDTRONIC'S SURGICAL BUSINESS AND ITS PURPOSEFUL LAUNCH OF THE HUGO RAS SYSTEM, WHICH RECEIVED FDA CLEARANCE FOR UROLOGIC SURGICAL PROCEDURES IN DECEMBER 2025 AND IS IN COMMERCIAL USE AT LEADING U.S. MEDICAL CENTERS.

MEDTRONIC SUBMITS 510(K) FILINGS TO EXPAND HUGO ROBOTIC-ASSISTED SURGERY SYSTEM INTO GENERAL AND GYNECOLOGIC SPECIALTIES IN THE UNITED STATES

INVESTMENTS IN INTRACARDIAC ECHOCARDIOGRAPHY (ICE) TECHNOLOGIES HIGHLIGHTMEDTRONIC'S COMMITMENT TO DRIVING DURABLE GROWTH IN THE CARDIAC ABLATION BUSINESS THROUGH A DIFFERENTIATED PORTFOLIO OF TECHNOLOGIES GALWAY,IRELAND, JUNE 3, 2026 /PRNEWSWIRE/ -- MEDTRONIC PLC (NYSE: MDT), A GLOBAL LEADER IN HEALTHCARE TECHNOLOGY, TODAY ANNOUNCED STRATEGIC INVESTMENTS IN TWO PRIVATELY HELD COMPANIES FOCUSED ON THE DEVELOPMENT OF INTRACARDIAC ECHOCARDIOGRAPHY (ICE) CATHETER TECHNOLOGIES. ICE CATHETERS PROVIDE REAL-TIME, HIGH-RESOLUTION IMAGING OF THE HEART DURING ELECTROPHYSIOLOGY (EP) PROCEDURES FOR CARDIAC ARRHYTHMIAS SUCH AS ATRIAL FIBRILLATION (AFIB).

MEDTRONIC ANNOUNCES STRATEGIC INVESTMENTS TO SUPPORT FUTURE EXPANSION OF CARDIAC ABLATION PORTFOLIO AS PHYSICIAN DEMAND FOR AFFERA TECHNOLOGIES BROADENS

DISCIPLINED EXECUTION AND PORTFOLIO STRENGTH POSITION MEDTRONIC FOR CONTINUED MOMENTUM INTO FISCAL YEAR 2027 GALWAY, IRELAND, JUNE 3, 2026 /PRNEWSWIRE/ -- MEDTRONIC PLC (NYSE: MDT), A GLOBAL LEADER IN HEALTHCARE TECHNOLOGY, TODAY ANNOUNCED FINANCIAL RESULTS FOR ITS FOURTH QUARTER (Q4) AND FISCAL YEAR 2026 (FY26), WHICH ENDED APRIL 24, 2026. Q4 KEY HIGHLIGHTS REVENUE OF $9.8 BILLION, INCREASED 9.9% AS REPORTED AND 6.6% ORGANIC, 90 BASIS POINTS AHEAD OF Q4 IMPLIED GUIDANCE GAAP DILUTED EPS OF $0.96; NON-GAAP DILUTED EPS OF $1.55, AHEAD OF GUIDANCE CARDIAC ABLATION SOLUTIONS REVENUE INCREASED 78% GLOBALLY, INCLUDING 124% U.S. GROWTH, GAINING AN ADDITIONAL 8 POINTS OF U.S. SHARE CARDIOVASCULAR GREW 10.1%, LED BY MID-SINGLE-DIGIT GROWTH IN CARDIAC RHYTHM MANAGEMENT DRIVEN BY CONTINUED STRENGTH ACROSS CARDIAC PACING THERAPIES AND DEFIBRILLATION SOLUTIONS, INCLUDING MID-TEENS GROWTH IN MICRA AND A STRONG OMNIASECURE U.S. LAUNCH MEDICAL SURGICAL REPORTED STRONG PERFORMANCE, UP 5.1%, LED BY ACUTE CARE & MONITORING AND ENDOSCOPY, WHICH WERE UP LOW-DOUBLE-DIGITS AND HIGH-SINGLE-DIGITS, RESPECTIVELY FILED SUBMISSION TO U.S. FDA FOR HUGO RAS FOR THE GENERAL SURGERY AND GYNECOLOGIC INDICATIONS, AS WELL AS LIGASURE RAS VESSEL SEALER; RECEIVED FDA CLEARANCE FOR PROGRIP ADVANCED SECURED FDA CLEARANCE FOR SPINE, CRANIAL AND ENT INDICATIONS AND CE MARK FOR SPINE AND CRANIAL INDICATIONS FOR STEALTH AXIS SURGICAL SYSTEM EXECUTED SEVERAL TUCK-IN M&A AND VENTURE CAPITAL TRANSACTIONS TO STRENGTHEN PORTFOLIOS, ACCELERATE GROWTH, AND EXPAND INTO HIGH-GROWTH ADJACENCIES: COMPLETED CATHWORKS ACQUISITION IN CORONARY AND RENAL DENERVATION; ANNOUNCED INTENTION TO ACQUIRE BOTH SCIENTIA VASCULAR IN NEUROVASCULAR AND SPR THERAPEUTICS IN NEUROMODULATION (IN MAY); ENTERED INTO AGREEMENTS WITH MERIT MEDICAL SYSTEMS TO OFFER VIAVERTE SYSTEM IN NEUROMODULATION; AND AN INVESTMENT IN PULNOVO MEDICAL IN CARDIOVASCULAR DIVIDEND FOR Q1 FY27 INCREASED TO $0.72 PER SHARE, IMPLYING ANNUAL $2.88 PER SHARE; 49TH C

MEDTRONIC REPORTS FOURTH QUARTER AND FULL YEAR FISCAL 2026 RESULTS; DELIVERS HIGHEST ANNUAL REVENUE GROWTH IN 10 YEARS

ACQUISITION WILL ENHANCE MEDTRONIC'S NEUROMODULATION PORTFOLIO WITH TEMPORARY PERIPHERAL NERVE STIMULATION (PNS) TECHNOLOGY, ENABLING EARLIER INTERVENTION FOR CHRONIC PAIN SUFFERERS GALWAY, IRELAND, MAY 20, 2026 /PRNEWSWIRE/ -- MEDTRONIC PLC (NYSE: MDT), A GLOBAL HEALTHCARE TECHNOLOGY LEADER, TODAY ANNOUNCED ITS INTENT TO ACQUIRE SPR THERAPEUTICS, INC. (SPR), A PRIVATELY HELD MEDICAL TECHNOLOGY COMPANY AND A RECOGNIZED LEADER IN TEMPORARY, PERCUTANEOUS PERIPHERAL NERVE STIMULATION (PNS) THERAPIES FOR CHRONIC PAIN MANAGEMENT. THE TRANSACTION CONSISTS OF AN UPFRONT CASH PAYMENT OF APPROXIMATELY $650 MILLION FOR ALL THE OUTSTANDING EQUITY IN SPR.

MEDTRONIC ANNOUNCES INTENT TO ACQUIRE SPR THERAPEUTICS, INC., EXPANDING CARE OPTIONS FOR PEOPLE LIVING WITH CHRONIC PAIN

PAYMENT FULFILLS PREVIOUSLY DISCLOSED FUNDING COMMITMENT OF $20 MILLION AND SUPPORTS PLANNED COMPLETION OF THE BACKBEAT GLOBAL PIVOTAL TRIAL (BACKBEAT TRIAL) EVALUATING ATRIOVENTRICULAR INTERVAL MODULATION THERAPY (AVIM THERAPY) IN PATIENTS WITH UNCONTROLLED HYPERTENSION AND AN INDICATION FOR A PACEMAKER AS PART OF THE STRATEGIC COLLABORATION BETWEEN ORCHESTRA BIOMED AND MEDTRONIC THIS PAYMENT, TOGETHER WITH $15 MILLION RECEIVED FROM LIGANDAND ANNOUNCED SEPARATELY, REPRESENTS A TOTAL OF $35 MILLION IN STRATEGIC CAPITAL RECEIVED UNDER PREVIOUSLY DISCLOSED AGREEMENTS NEW HOPE, PA., MAY 06, 2026 (GLOBE NEWSWIRE) -- ORCHESTRA BIOMED HOLDINGS, INC. (NASDAQ: OBIO) (ORCHESTRA BIOMED OR THE COMPANY), A BIOMEDICAL COMPANY ACCELERATING HIGH-IMPACT TECHNOLOGIES TO PATIENTS THROUGH STRATEGIC PARTNERSHIPS WITH MARKET-LEADING GLOBAL MEDICAL DEVICE COMPANIES, TODAY ANNOUNCED THE RECEIPT OF A $20 MILLION INVESTMENT FROM MEDTRONIC, PLC.

ORCHESTRA BIOMED RECEIVES $20 MILLION PAYMENT FROM MEDTRONIC UNDER PREVIOUSLY ANNOUNCED FINANCING AGREEMENT

ATRIOVENTRICULAR INTERVAL MODULATION (AVIM) THERAPY FOOD AND DRUG ADMINISTRATION (FDA) BREAKTHROUGH DEVICE DESIGNATIONS SPAN THE BROADER POPULATION OF PATIENTS WITH UNCONTROLLED HYPERTENSION DESPITE MEDICATION AT INCREASED CARDIOVASCULAR RISK AND THE SPECIFIC PACEMAKER-INDICATED POPULATION BEING EVALUATED IN THE BACKBEAT TRIAL THE ADDRESSABLE U.S. PATIENT POPULATION FOR AVIM THERAPY, BASED ON THE INDICATIONS FOR USE SPECIFIED IN ITS BREAKTHROUGH DEVICE DESIGNATIONS, COMPRISES OVER 7.7 MILLION ADULTS WITH HYPERTENSION DESPITE MEDICATION BREAKTHROUGH DEVICE DESIGNATION SUPPORTS FAVORABLE REIMBURSEMENT PATHWAYS, INCLUDING POTENTIAL ELIGIBILITY FOR NEW TECHNOLOGY ADD-ON PAYMENT (NTAP) AND TRANSITIONAL PASS-THROUGH (TPT) PAYMENT, WHICH CAN FACILITATE BROADER, MORE TIMELY PATIENT ACCESS AND PROVIDER ADOPTION NEW HOPE, PA., APRIL 30, 2026 (GLOBE NEWSWIRE) -- ORCHESTRA BIOMED HOLDINGS, INC. (NASDAQ: OBIO) (ORCHESTRA BIOMED OR THE COMPANY), A BIOMEDICAL COMPANY ACCELERATING HIGH-IMPACT TECHNOLOGIES TO PATIENTS THROUGH STRATEGIC PARTNERSHIPS WITH MARKET-LEADING GLOBAL MEDICAL DEVICE COMPANIES, TODAY ANNOUNCED THAT THE FDA HAS GRANTED A SECOND BREAKTHROUGH DEVICE DESIGNATION (BDD) FOR AVIM THERAPY SPECIFIC TO PATIENTS WITH UNCONTROLLED HYPERTENSION DESPITE THE USE OF ANTI-HYPERTENSIVE MEDICATIONS, AND AN INDICATION FOR A PACEMAKER.

Medtronic plc

MDT

Price

Financial Reports

No items found.

Press Releases

Medtronic plc

MDT.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

MDT